Alkermes (ALKS) Stock Forecast, Price & News

Alkermes (NASDAQ:ALKS) Frequently Asked Questions

Is Alkermes a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes or view top-rated stocks.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Alkermes.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) posted its quarterly earnings data on Wednesday, April, 27th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.11. The company had revenue of $278.55 million for the quarter, compared to analysts' expectations of $256.02 million. Alkermes had a positive trailing twelve-month return on equity of 3.87% and a negative net margin of 5.13%. The firm's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.01 earnings per share.
View Alkermes' earnings history.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided EPS guidance of $(0.18)-0.00 for the period, compared to the consensus estimate of ($0.10). The company issued revenue guidance of $1.00-1.09 billion, compared to the consensus revenue estimate of $1.05 billion.

What price target have analysts set for ALKS?

9 analysts have issued 12-month price objectives for Alkermes' stock. Their forecasts range from $25.00 to $36.00. On average, they expect Alkermes' stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 2.2% from the stock's current price.
View analysts' price targets for Alkermes or view top-rated stocks among Wall Street analysts.

Who are Alkermes' key executives?

Alkermes' management team includes the following people:

• Mr. Richard F. Pops, Chairman & CEO (Age 60, Pay $2M)
• Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 50, Pay $839.91k) (LinkedIn Profile)
• Mr. Michael J. Landine, Sr. VP of Corp. Devel. & Chief Risk Officer (Age 68, Pay $750.46k) (LinkedIn Profile)
• Dr. Craig C. Hopkinson, Exec. VP of R&D and Chief Medical Officer (Age 54, Pay $1.02M) (LinkedIn Profile)
• Dr. Floyd E. Bloom M.D., Founder (Age 85)
• Mr. Iain Michael Brown, Sr. VP & CFO (Age 53) (LinkedIn Profile)
• Mr. Blair C. Jackson, Exec. VP & COO (Age 49)
• Ms. Sandra Coombs, Sr. VP of Corp. Affairs & Investor Relations
• Mr. Stephen Schiavo, Sr. VP of HR
• Mr. Peter Norman, Sr. VP of Policy & Gov. Relations

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes CEO Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among Alkermes' employees.

Who are some of Alkermes' key competitors?

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO) and Exelixis (EXEL).
View all of ALKS's competitors.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.28%), BlackRock Inc. (9.23%), Wellington Management Group LLP (7.02%), State Street Corp (3.54%), Primecap Management Co. CA (3.47%) and Hardman Johnston Global Advisors LLC (3.22%). Company insiders that own Alkermes stock include Blair Curtis Jackson, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends for Alkermes.

Which institutional investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Federated Hermes Inc., Wellington Management Group LLP, Bank of New York Mellon Corp, Woodline Partners LP, Hardman Johnston Global Advisors LLC, Russell Investments Group Ltd., and Edgestream Partners L.P.. Company insiders that have sold Alkermes company stock in the last year include Blair Curtis Jackson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Michael J Landine, Richard F Pops, Shane Cooke, and Wendy L Dixon.
View insider buying and selling activity for Alkermes or view top insider-selling stocks.

Which institutional investors are buying Alkermes stock?

ALKS stock was purchased by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, BlackRock Inc., Teacher Retirement System of Texas, Eagle Asset Management Inc., Goldman Sachs Group Inc., Integral Health Asset Management LLC, JPMorgan Chase & Co., and State Street Corp.
View insider buying and selling activity for Alkermes or or view top insider-buying stocks.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $30.00.

How much money does Alkermes make?

Alkermes has a market capitalization of $4.90 billion and generates $1.17 billion in revenue each year. The company earns $-48.17 million in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does Alkermes have?

Alkermes employs 2,211 workers across the globe.

Does Alkermes have any subsidiaries?

The following companies are subsidiares of Alkermes: Rodin Therapeutics.

When was Alkermes founded?

Alkermes was founded in 1987.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000, via email at [email protected], or via fax at 781-890-0524.